Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 128

1.

Targeting Bruton's tyrosine kinase in B cell malignancies.

Hendriks RW, Yuvaraj S, Kil LP.

Nat Rev Cancer. 2014 Apr;14(4):219-32. doi: 10.1038/nrc3702. Review.

PMID:
24658273
[PubMed - indexed for MEDLINE]
2.

Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies.

Lou Y, Owens TD, Kuglstatter A, Kondru RK, Goldstein DM.

J Med Chem. 2012 May 24;55(10):4539-50. doi: 10.1021/jm300035p. Epub 2012 Mar 21. Review. No abstract available.

PMID:
22394077
[PubMed - indexed for MEDLINE]
3.

Bruton's tyrosine kinase as a drug discovery target.

Pan Z.

Drug News Perspect. 2008 Sep;21(7):357-62. doi: 10.1358/dnp.2008.21.7.1255308. Review.

PMID:
19259548
[PubMed - indexed for MEDLINE]
4.

B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.

Hill RJ, Lou Y, Tan SL.

Int Rev Immunol. 2013 Aug;32(4):377-96. doi: 10.3109/08830185.2013.818141. Review.

PMID:
23886341
[PubMed - indexed for MEDLINE]
5.

Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.

Robak T, Robak E.

Expert Opin Investig Drugs. 2012 Jul;21(7):921-47. doi: 10.1517/13543784.2012.685650. Epub 2012 May 22. Review.

PMID:
22612424
[PubMed - indexed for MEDLINE]
6.

PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies.

Winer ES, Ingham RR, Castillo JJ.

Expert Opin Investig Drugs. 2012 Mar;21(3):355-61. doi: 10.1517/13543784.2012.656199. Epub 2012 Feb 3. Review.

PMID:
22300471
[PubMed - indexed for MEDLINE]
7.

Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).

Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA, Smith LL, Dubovsky JA, Towns WH, MacMurray J, Harrington BK, Davis ME, Gobessi S, Laurenti L, Chang BY, Buggy JJ, Efremov DG, Byrd JC, Johnson AJ.

Blood. 2014 Feb 20;123(8):1207-13. doi: 10.1182/blood-2013-07-515361. Epub 2013 Dec 5.

PMID:
24311722
[PubMed - indexed for MEDLINE]
8.

Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives.

Tan SL, Liao C, Lucas MC, Stevenson C, DeMartino JA.

Pharmacol Ther. 2013 May;138(2):294-309. doi: 10.1016/j.pharmthera.2013.02.001. Epub 2013 Feb 7. Review.

PMID:
23396081
[PubMed - indexed for MEDLINE]
9.

Ibrutinib and novel BTK inhibitors in clinical development.

Akinleye A, Chen Y, Mukhi N, Song Y, Liu D.

J Hematol Oncol. 2013 Aug 19;6:59. doi: 10.1186/1756-8722-6-59. Review.

PMID:
23958373
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Targeted therapy in chronic lymphocytic leukemia: past, present, and future.

Danilov AV.

Clin Ther. 2013 Sep;35(9):1258-70. doi: 10.1016/j.clinthera.2013.08.004. Review.

PMID:
24054703
[PubMed - indexed for MEDLINE]
11.

Clinical potential of targeting Bruton's tyrosine kinase.

Uckun FM.

Int Rev Immunol. 2008 Jan-Apr;27(1-2):43-69. doi: 10.1080/08830180701784588. Review.

PMID:
18300055
[PubMed - indexed for MEDLINE]
13.

BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.

Robak T, Robak P.

Int Rev Immunol. 2013 Aug;32(4):358-76. doi: 10.3109/08830185.2013.786711. Epub 2013 Apr 25. Review.

PMID:
23617253
[PubMed - indexed for MEDLINE]
14.

[Ibrutinib in the treatment of chronic lymphocytic leukemia and other B-cell malignancies].

Wang M, Xu W, Li JY.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Feb;22(1):245-9. doi: 10.7534/j.issn.1009-2137.2014.01.049. Review. Chinese.

PMID:
24598688
[PubMed - indexed for MEDLINE]
15.

The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways.

Kenkre VP, Kahl BS.

Curr Hematol Malig Rep. 2012 Sep;7(3):216-20. doi: 10.1007/s11899-012-0127-0. Review.

PMID:
22688757
[PubMed - indexed for MEDLINE]
16.

Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape.

Burger JA.

Curr Opin Oncol. 2012 Nov;24(6):643-9. doi: 10.1097/CCO.0b013e3283589950. Review.

PMID:
22960555
[PubMed - indexed for MEDLINE]
17.

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.

Rushworth SA, Murray MY, Zaitseva L, Bowles KM, MacEwan DJ.

Blood. 2014 Feb 20;123(8):1229-38. doi: 10.1182/blood-2013-06-511154. Epub 2013 Dec 4.

PMID:
24307721
[PubMed - indexed for MEDLINE]
18.

Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.

MacPartlin M, Smith AM, Druker BJ, Honigberg LA, Deininger MW.

Leukemia. 2008 Jul;22(7):1354-60. doi: 10.1038/leu.2008.126. Epub 2008 Jun 12.

PMID:
18548107
[PubMed - indexed for MEDLINE]
19.

B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies.

Puri KD, Di Paolo JA, Gold MR.

Int Rev Immunol. 2013 Aug;32(4):397-427. doi: 10.3109/08830185.2013.818140. Review.

PMID:
23886342
[PubMed - indexed for MEDLINE]
20.

Identification of the SH2 domain binding protein of Bruton's tyrosine kinase as BLNK--functional significance of Btk-SH2 domain in B-cell antigen receptor-coupled calcium signaling.

Hashimoto S, Iwamatsu A, Ishiai M, Okawa K, Yamadori T, Matsushita M, Baba Y, Kishimoto T, Kurosaki T, Tsukada S.

Blood. 1999 Oct 1;94(7):2357-64.

PMID:
10498607
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk